Gene · 1024
Papers2,191
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
541 to 560 of 2,191
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Effect of Liposomal Diallyl Disulfide and Oxaliplatin on Proliferation of Colorectal Cancer Cells: In Vitro and In Silico Analysis. | Pharmaceutics | 2022 | 35213970 | PubTator, text mining | PubMed |
| The Bright and the Dark Side of TGF-β Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications. | Cancers (Basel) | 2022 | 35205692 | PubTator, text mining | PubMed |
| Molecularly Guided Drug Repurposing for Cholangiocarcinoma: An Integrative Bioinformatic Approach. | Genes (Basel) | 2022 | 35205315 | PubTator, text mining | PubMed |
| Role of the Mediator Complex and MicroRNAs in Breast Cancer Etiology. | Genes (Basel) | 2022 | 35205279 | PubTator, text mining | PubMed |
| Hepatitis A Virus Cellular Receptor 1 (HAVcr-1) Initiates Prostate Cancer Progression in Human Cells via Hepatocyte Growth Factor (HGF)-Induced Changes in Junctional Integrity. | Biomolecules | 2022 | 35204839 | PubTator, text mining | PubMed |
| Aberrant cyclin C nuclear release induces mitochondrial fragmentation and dysfunction in MED13L syndrome fibroblasts. | iScience | 2022 | 35198885 | PubTator, text mining | PubMed |
| The Mediator kinase module: an interface between cell signaling and transcription. | Trends Biochem Sci | 2022 | 35193797 | PubTator, text mining | PubMed |
| A curious case of cyclin-dependent kinases in neutrophils. | J Leukoc Biol | 2022 | 35188696 | PubTator, text mining | PubMed |
| Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses Its Pro-Oncogenic Effects in Prostate Cancer. | Am J Pathol | 2022 | 35181333 | PubTator, text mining | PubMed |
| In leukemia, knock-down of the death inducer-obliterator gene would inhibit the proliferation of endothelial cells by inhibiting the expression of CDK6 and CCND1. | PeerJ | 2022 | 35178295 | PubTator, text mining | PubMed |
| A Network Pharmacology Study on the Active Components and Targets of the Radix Ginseng and Radix Bupleuri Herb Pair for Treating Nonalcoholic Fatty Liver Disease. | Evid Based Complement Alternat Med | 2022 | 35178098 | PubTator, text mining | PubMed |
| Circular RNA circ_0068464 combined with microRNA-383 regulates Wnt/β-catenin pathway to promote the progression of colorectal cancer. | Bioengineered | 2022 | 35168468 | PubTator, text mining | PubMed |
| Cell Cycle-Dependent Transcription: The Cyclin Dependent Kinase Cdk1 Is a Direct Regulator of Basal Transcription Machineries. | Int J Mol Sci | 2022 | 35163213 | PubTator, text mining | PubMed |
| Dissecting TET2 Regulatory Networks in Blood Differentiation and Cancer. | Cancers (Basel) | 2022 | 35159097 | PubTator, text mining | PubMed |
| Transcriptional Coactivators: Driving Force of Plant Immunity. | Front Plant Sci | 2022 | 35154230 | PubTator, text mining | PubMed |
| Cordycepin inhibits colon cancer proliferation by suppressing MYC expression. | BMC Pharmacol Toxicol | 2022 | 35120580 | PubTator, text mining | PubMed |
| Systems approaches to understand oxygen sensing: how multi-omics has driven advances in understanding oxygen-based signalling. | Biochem J | 2022 | 35119457 | PubTator, text mining | PubMed |
| Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer. | Mol Pharmacol | 2022 | 35115411 | PubTator, text mining | PubMed |
| A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. | J Med Chem | 2022 | 35114084 | PubTator, text mining | PubMed |
| The role of mediator subunit 12 in tumorigenesis and cancer therapeutics. | Oncol Lett | 2022 | 35111243 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1024/papers?page=28